CAS NO: | 23214-92-8 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | Doxorubicin (Hydroxydaunorubicin), a cytotoxic anthracyclineantibiotic, is an anti-cancer chemotherapy agent. Doxorubicin inhibitstopoisomeraseIIwith anIC50of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation ofAMPKand its downstream targetacetyl-CoA carboxylase. Doxorubicin inducesapoptosisandautophagy[1][2]. Doxorubicin inhibits humanDNAtopoisomeraseIwith anIC50of 0.8 μM[3]. | ||||
IC50& Target[1][2][3][7] |
| ||||
体外研究 (In Vitro) | Combination of Doxorubicin (Hydroxydaunorubicin) and Simvastatin in the highest tested concentrations (2 μM and 10 μM, respec-tively) kills 97% of the Hela cells[4]. | ||||
体内研究 (In Vivo) | Mice bearing PC3 xenografts are injected with 2, 4 or 8 mg/kg Doxorubicin (Hydroxydaunorubicin) and tumor volume is measured over time. A dose of 2 mg/kg does not affect tumor growth while higher dosages delay tumor growth initially (p<0.05 at days 18 and 22), 4 mg/kg or 8 mg/kg Doxorubicin significantly reduces levels of c-FLIP in PC3 xenografts[5]. A single intraperitoneal injection 10 mg/kg (Doxorubicin 1) is administered in rats, 10 daily intraperitoneal injections of 1 mg/kg (Doxorubicin 2), or in 5 weekly intraperitoneal injections of 2 mg/kg (Doxorubicin 3). An 80% mortality rate is observed at day 28 in Doxorubicin 1, whereas Doxorubicin 2 and Doxorubicin 3 reached 80% mortality at days 107 and 98, respectively. Fractional shortening decreased by 30% at week 2 in Doxorubicin DOX1, 55% at week 13 in Doxorubicin 2, and 42% at week 13 in Doxorubicin 3[6]. | ||||
Clinical Trial | |||||
分子量 | 543.52 | ||||
Formula | C27H29NO11 | ||||
CAS 号 | 23214-92-8 | ||||
中文名称 | 阿霉素;多柔比星 | ||||
结构分类 |
| ||||
来源 | Streptomyces peucetius. | ||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. | ||||
溶解性数据 | In Vivo:
|